Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Treasury Shares (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Treasury Shares for 7 consecutive years, with $16.5 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 23.86% to $16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Dec 2025, up 23.86% year-over-year, with the annual reading at $16.5 million for FY2025, 23.86% up from the prior year.
  • Treasury Shares hit $16.5 million in Q4 2025 for Allogene Therapeutics, up from $4.7 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $17.2 million in Q2 2025 to a low of $3.1 million in Q1 2021.
  • Historically, Treasury Shares has averaged $9.2 million across 5 years, with a median of $9.2 million in 2022.
  • Biggest five-year swings in Treasury Shares: skyrocketed 146.5% in 2023 and later crashed 65.39% in 2025.
  • Year by year, Treasury Shares stood at $4.3 million in 2021, then increased by 28.92% to $5.5 million in 2022, then skyrocketed by 121.73% to $12.2 million in 2023, then rose by 9.55% to $13.3 million in 2024, then rose by 23.86% to $16.5 million in 2025.
  • Business Quant data shows Treasury Shares for ALLO at $16.5 million in Q4 2025, $4.7 million in Q3 2025, and $17.2 million in Q2 2025.